Multinational phase 3 study of lutetium-177-PSMA-617 for previously treated mCRPC

Prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC lesions. Lutetium-177 –PSMA-617 is a targeted radioligand therapy delivering β-particle radiation to PSMA-expressing cells. The multination phase 3 study VISION evaluated this therapy for previously treated PSMA-positive mCRPC. The median rPFS was 8.7 months in the treated group versus 3.4 months in the control group (HR 0.40; p<0.001) and the median OS was 15.3 versus 11.3 months (HR 0.62; p<0.001). The therapy was well tolerated.